Randomized phase II study of docetaxel (D) plus abiraterone acetate (AA) versus D after disease progression to first-line AA in metastatic castration-resistant prostate cancer (mCRPC): ABIDO-SOGUG Trial

被引：0

作者：

Climent Duran, Miguel Angel

Font, Albert

Duran, Ignacio

Puente, Javier

Castellano, Daniel

Isabel Saez, M.

Mendez Vidal, Maria Jose Jose

Santander, Carmen

Arranz Arija, Jose Angel

Gonzalez del Alba, Aranzazu

Sanchez-Hernandez, Alfredo

Esteban, Emilio

Alonso Gordoa, Teresa

Maroto, Pablo

Lazaro Quintela, Martin Emilio

Cassinello, Javier

Perez Valderrama, Begona

Juan Fita, Maria Jose

Mellado, Begona

机构：

[1] Inst Valenciano Oncol, Valencia, Spain

[2] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

[3] Hosp Univ Marques Valdecilla, Santander, Spain

[4] Hosp Univ Clin San Carlos, Madrid, Spain

[5] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[6] Hosp Univ Virgen Victoria & Reg Malaga, Inst Biomed Res Malaga, CRIS Canc Fdn, Prostate Canc Res Grp,CNIOIBIMA Genitourinary Can, Malaga, Spain

[7] Hosp Univ Reina Sofia, Cordoba, Spain

[8] Hosp Univ Miguel Servet, Zaragoza, Spain

[9] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[10] Hosp Univ Puerta Hierro Majadahonda, Med Oncol Dept, Palma de Mallorca, Spain

[11] Hosp Prov Castellon, Castellon de La Plana, Spain

[12] Hosp Univ Cent Asturias, Asturias, Spain

[13] Hosp Univ Ramon y Cajal, Madrid, Spain

[14] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[15] Hosp Univ Vigo, Vigo, Spain

[16] Hosp Univ Guadalajara, Guadalajara, Spain

[17] Hosp Univ Virgen Rocio, Seville, Spain

[18] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumours, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2